Literature DB >> 6604733

Effect of renal function on plasma levels of bone Gla-protein.

P D Delmas, D M Wilson, K G Mann, B L Riggs.   

Abstract

Plasma bone Gla-protein (BGP) is a sensitive and specific marker for metabolic bone disease. Because BGP is removed from the circulation mainly by kidney clearance, increased plasma BGP in subjects with impaired renal function could be due to decreased renal clearance, increased bone metabolism, or both. These factors were evaluated in 62 patients with various degrees of renal failure in whom we measured plasma BGP, [125I]iothalamate clearance [a measure of glomerular filtration rate (GFR)], and [131I]o-iodohippurate clearance (a measure of effective renal plasma flow). In all patients with GFR greater than 30 ml/min X 1.73 m2, plasma BGP was within the normal range for age- and sex-comparable control subjects, and large increases in plasma BGP did not occur until GFR was below 20 ml/min X 1.73 m2. Nonlinear regression analysis showed that the variation in plasma BGP was substantially accounted for using the exponential of GFR. Similarly, plasma BGP was normal for values of effective renal plasma flow above 150 ml/min X 1.73 m2. Thus, for normal subjects and patients with mild to moderate renal failure, plasma elevations of BGP reflect increased bone turnover rather than decreased renal filtration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604733     DOI: 10.1210/jcem-57-5-1028

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  39 in total

1.  Chronic renal failure in hip fracture patients.

Authors:  Miriam Casey; Bernard Walsh
Journal:  Osteoporos Int       Date:  2004-03-30       Impact factor: 4.507

Review 2.  Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2010-12-03       Impact factor: 5.992

Review 3.  Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength.

Authors:  Meghan E McGee-Lawrence; Hannah V Carey; Seth W Donahue
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-08       Impact factor: 3.619

4.  Biochemical bone markers compared with bone density measurement by dual energy X-ray absorptiometry.

Authors:  J Lotz; D Steeger; G Hafner; W Ehrenthal; J Heine; W Prellwitz
Journal:  Calcif Tissue Int       Date:  1995-10       Impact factor: 4.333

5.  Metabolism of osteocalcin.

Authors:  W Farrugia; R A Melick
Journal:  Calcif Tissue Int       Date:  1986-10       Impact factor: 4.333

6.  Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein.

Authors:  K Brixen; H K Nielsen; E F Eriksen; P Charles; L Mosekilde
Journal:  Calcif Tissue Int       Date:  1989-02       Impact factor: 4.333

Review 7.  Endocrine regulation of bone and energy metabolism in hibernating mammals.

Authors:  Alison H Doherty; Gregory L Florant; Seth W Donahue
Journal:  Integr Comp Biol       Date:  2014-02-19       Impact factor: 3.326

8.  Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism.

Authors:  M Katagiri; T Ohtawa; M Fukunaga; T Harada
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Serum osteocalcin and fracture susceptibility in elderly women.

Authors:  K Akesson; S Ljunghall; P Gärdsell; I Sernbo; K J Obrant
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

Review 10.  Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  P Bergmann; J-J Body; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; J-Y Reginster; V Gangji
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.